Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487916 | 1.00 | MET (0.50) | METJAK2MAP4K3MAP4K4BRAF | |
| SCHEMBL487979 | 0.91 | MET (0.45) | METJAK2MAP4K3MAP4K4RIPK2 | |
| SCHEMBL30453826 | 0.91 | MET (0.45) | METJAK2MAP4K3MAP4K4RIPK2 | |
| SCHEMBL30452927 | 0.89 | MET (0.49) | METJAK2MAP4K3MAP4K4BRAF | |
| SCHEMBL488262 | 0.89 | MET (0.49) | METJAK2MAP4K3MAP4K4BRAF | |
| SCHEMBL487823 | 0.85 | CSF1R (0.37) | METMAP4K3 | |
| SCHEMBL30452931 | 0.85 | CSF1R (0.37) | METMAP4K3 | |
| SCHEMBL30452637 | 0.83 | MET (0.54) | METJAK2MAP4K3 | |
| SCHEMBL488277 | 0.83 | MET (0.54) | METJAK2MAP4K3 | |
| SCHEMBL488526 | 0.83 | MET (0.57) | METJAK2MAP4K3RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4599890-A2 | SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2025-08-13 | — | — | EP | disclosed |
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |